Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Releases

499 Press Releases
DateTitleCompany
19 Sep 17 Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO® (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
19 Sep 17 Teva Completes Amendment to Credit Facilities Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Sep 17 New Initiative Creates Scalable Solutions to Improve Care of Patients with Multiple Chronic Conditions Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Sep 17 Teva Announces Sale of Remaining Assets in Specialty Global Women’s Health Portfolio for $1.38 Billion Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
12 Sep 17 Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Sep 17 Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Sep 17 Teva Names Kåre Schultz as President and Chief Executive Officer Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
09 Sep 17 Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Sep 17 Teva to Present Fremanezumab Data on Migraine Prevention at the 18th Congress of the International Headache Society Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
30 Aug 17 Teva Announces FDA Approval of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Aug 17 Teva Announces Exclusive Launch of Generic Axiron® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
07 Aug 17 Teva Announces FDA Approval of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 Jul 17 Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin® (trastuzumab) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
28 Jul 17 Teva Announces Launch of Generic Epiduo® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
24 Jul 17 Teva Announces the Launch of Generic Vagifem® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
20 Jul 17 NICE Recommends CINQAERO® (reslizumab) for the Treatment of Severe Eosinophilic Asthma Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
13 Jul 17 Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Jul 17 Teva to Report Second Quarter 2017 Financial Results on August 3, 2017 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
07 Jun 17 Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
17 May 17 Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual Meeting Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
27 Jun 17 Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc.,
Published by
Business Wire
29 Jun 17 Teva Announces Publication of AIM-TD Study Results in The Lancet Psychiatry for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
29 Jun 17 Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab) Teva Pharmaceutical Industries Ltd. and Celltrion, Inc.,
Published by
Business Wire
09 Jun 17 Teva Announces Exclusive Launch of Generic Pataday® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Jun 17 Teva to Present at the Jefferies 2017 Global Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
15 May 17 Teva Announces Launch of Generic Glumetza® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 May 17 Teva Announces Positive Results for Phase III Study of Fremanezumab for the Prevention of Chronic Migraine Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Jul 17 Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
12 Jun 17 Teva Announces Launch of Generic Zetia® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
01 Jun 17 Teva to Present Data from 18 Abstracts in Tardive Dyskinesia and Huntington Disease at the 21st International Congress of Parkinson’s Disease and Movement Disorders Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.